Literature DB >> 6611324

Role of T-lymphocytes in the pathogenesis of herpetic stromal keratitis.

R G Russell, M P Nasisse, H S Larsen, B T Rouse.   

Abstract

Our study was designed to investigate the mechanism of the stromal reaction in experimental ocular infection of murine eyes with herpes simplex virus (HSV). Severe stromal keratitis with scarring occurred in BALB/c mice after infection of the scarified cornea but similar reactions did not occur in athymic mice. However, if athymic mice were given adoptive transfers of lymphoid cells, a severe necrotizing and ulcerative keratitis accompanied by scarring resulted. The lesion progressed more quickly in recipients of lymphoid cells specifically immune to HSV and containing cytotoxic T-lymphocyte activity. In such mice, necrosis and ulceration were marked on the sixth day after transfer compared with 9-12 days for those given nonimmune cells. Removal of T-lymphocytes from the immune lymphoid population by treatment with specific antiserum and complement abrogated the adoptive transfer of the stromal reaction. Our results further demonstrate that stromal keratitis represents a host immunopathologic response to HSV infection in which T-lymphocytes are essential participants. Multiple mechanisms of T-cell immunopathology appear to be operating, including a reaction mediated by cytotoxic T-lymphocytes.

Entities:  

Mesh:

Year:  1984        PMID: 6611324

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  54 in total

1.  Pathogenesis of herpes simplex virus type 1-induced corneal inflammation in perforin-deficient mice.

Authors:  E Chang; L Galle; D Maggs; D M Estes; W J Mitchell
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Herpes simplex keratitis in renal transplant patients.

Authors:  I Kremer; A Wagner; D Shmuel; A Yussim; Z Shapira
Journal:  Br J Ophthalmol       Date:  1991-02       Impact factor: 4.638

3.  CD8 T cells mediate transient herpes stromal keratitis in CD4-deficient mice.

Authors:  Andrew J Lepisto; Gregory M Frank; Min Xu; Patrick M Stuart; Robert L Hendricks
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-08       Impact factor: 4.799

4.  Therapeutic immunization with a virion host shutoff-defective, replication-incompetent herpes simplex virus type 1 strain limits recurrent herpetic ocular infection.

Authors:  Tammie L Keadle; Lynda A Morrison; Jessica L Morris; Jay S Pepose; Patrick M Stuart
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

5.  Activation of endothelial roundabout receptor 4 reduces the severity of virus-induced keratitis.

Authors:  Sachin Mulik; Shalini Sharma; Amol Suryawanshi; Tamara Veiga-Parga; Pradeep B J Reddy; Naveen K Rajasagi; Barry T Rouse
Journal:  J Immunol       Date:  2011-05-13       Impact factor: 5.422

Review 6.  Host immune cellular reactions in corneal neovascularization.

Authors:  Nizar S Abdelfattah; Mohamed Amgad; Amira A Zayed
Journal:  Int J Ophthalmol       Date:  2016-04-18       Impact factor: 1.779

7.  Induction of interleukin-8 gene expression is associated with herpes simplex virus infection of human corneal keratocytes but not human corneal epithelial cells.

Authors:  J E Oakes; C A Monteiro; C L Cubitt; R N Lausch
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

8.  Activated inflammatory infiltrate in HSV-1-infected corneas without herpes stromal keratitis.

Authors:  Sherrie J Divito; Robert L Hendricks
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04       Impact factor: 4.799

9.  Influence of dimethylfumarate on experimental HSV-1 necrotizing keratitis.

Authors:  A Heiligenhaus; H Li; S Wasmuth; D Bauer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-07-06       Impact factor: 3.117

10.  Anti-glycoprotein D monoclonal antibody protects against herpes simplex virus type 1-induced diseases in mice functionally depleted of selected T-cell subsets or asialo GM1+ cells.

Authors:  H F Staats; J E Oakes; R N Lausch
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.